Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lurbinectedin in FET-Fusion Tumors (LIFFT)

NCT05918640 is registered in ClinicalTrials.gov with Children's Hospital of Philadelphia as lead sponsor.

NCT NCT05918640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lurbinectedin in FET-Fusion Tumors (LIFFT)
Lead sponsor
Children's Hospital of Philadelphia
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 27, 2023
Completion date
July 30, 2029
Enrollment
63 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

desmoplastic small round cell tumor, ewing sarcoma, pediatric cancer, undifferentiated sarcoma